Boron neutron capture therapy for clear cell sarcoma. (December 2020)

• Record Type: Journal Article
• Authors: Fujimoto, Takuya; Suzuki, Minoru; Sudo, Tamotsu; Fujita, Ikuo; Sakuma, Toshiko; Sakurai, Yoshinori; Hirose, Takanori; Morishita, Masayuki; Takata, Takushi; Tamari, Yuki; Tanaka, Hiroki; Andoh, Tooru; Kawamoto, Teruya; Hara, Hitomi; Fukase, Naomasa; Kawakami, Yohei; Shigemoto, Rika; Matsumoto, Tomoyuki; Ichikawa, Hideki; Ono, Koji; Kuroda, Ryosuke; Akisue, Toshihiro
• Is Part Of: Applied radiation and isotopes. Volume 166(2020:Dec.)
• Publication Date: 2020-12
• Subjects: Clear cell sarcoma of tendons and aponeuroses -- Boron neutron capture therapy (BNCT) -- p-borono-l-phenylalanine (BPA) -- Clinical treatment -- L-type amino acid transporter 1 (LAT1) -- CD98; Radiology -- Periodicals; Radiation -- Industrial applications -- Periodicals; Nuclear chemistry -- Periodicals; Internet resource; Periodical; 660.298
• DOI: 10.1016/j.apradiso.2020.109324
• Languages: English
• ISSNs: 0969-8043

Abstract

Abstract: Clear cell sarcoma of tendons and aponeuroses (CCS) is a rare, malignant tumor arising in lower extremities with no effective treatment other than wide surgical resection. Here described is a case of primary CCS in the peroneal tendon of the right foot of a 54-year-old woman enrolled to undergo BNCT. The tumor mass post-BNCT disappeared totally without damage to other normal tissue, demonstrating, for the first time, the potential efficacy of BNCT in complete local control of CCS. Highlights: First ever BNCT for clear cell sarcoma in tendon on right foot of 54-year-old woman. Two deferred courses of BNCT irradiation to two sides of foot eradicated the CCS. CCS cells expressing LAT1 uptake BPA selectively rendering them susceptible to BNCT.